Teduglutide CAS:197922-42-2

Teduglutide is indicated for the management of short bowel syndrome (SBS) in adults who are dependent on parenteral support. This condition is characterized by significant intestinal resection, leading to malabsorption, diarrhea, fluid and electrolyte imbalances, and the need for intravenous nutrition. As a synthetic analog of GLP-2, teduglutide acts locally in the gastrointestinal tract to promote mucosal growth, increase nutrient absorption, and reduce the reliance on parenteral support. The recommended dosage of teduglutide is administered subcutaneously once daily, typically after reconstitution of the lyophilized powder with diluent provided in the product packaging. Close monitoring and individualized dosing regimens are essential elements of patient management to ensure optimal outcomes and adherence to the prescribed treatment plan. In clinical trials, teduglutide has demonstrated efficacy in reducing the volume and frequency of parenteral support required by patients with SBS, consequently improving their overall nutritional status and quality of life. Its ability to enhance intestinal adaptation and function makes it a valuable therapeutic option for individuals with this challenging and debilitating condition. In addition to its role as a monotherapy, teduglutide may also be used in combination with other interventions aimed at managing SBS, such as dietary modifications, fluid and electrolyte balance, and pharmacologic agents targeting specific symptoms or complications associated with the syndrome. Close collaboration between healthcare providers and patients is essential for integrating teduglutide into the overall management plan, tailoring therapy to individual needs, and optimizing the balance between therapeutic efficacy and quality of life. While generally well-tolerated, teduglutide may be associated with side effects such as abdominal pain, nausea, and headaches. Patient education and close monitoring are essential components of care to address potential side effects and ensure optimal outcomes. In summary, teduglutide represents a crucial tool in the management of short bowel syndrome, offering a targeted approach to promoting intestinal adaptation, enhancing nutrient absorption, and reducing dependency on parenteral support. Collaborative and comprehensive care is essential for harnessing the potential benefits of teduglutide, addressing patient-specific needs, and optimizing the overall management of this complex and